LLM returned non-JSON response. Review the filing manually.
KROS drugs
KROS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $11.71entry
- T+1 · 9mo ago −3.50%α −2.19% · $11.30
- T+5 · 8mo ago −6.15%α −3.91% · $10.99
- T+20 · 8mo ago +2.48%α +6.27% · $12.00
- T+60 · 6mo ago −6.92%α −18.22% · $10.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
{ "summary": "Keros Therapeutics reported a full-year net income of $87.0 million for 2025, a significant improvement from a $187.4 million net loss in 2024, primarily due to $205.4 million in license revenue from Takeda. The company also announced leadership changes and upcoming clinical trial milestones for rinvatercept in DMD and ALS. Cash reserves declined to $287.4 million from $559.9 million, largely due to a share repurchase and tender offer.", "sentiment": "mixed", "impactScore": 6
Financial Impact
Unknown
Risk Factors
- Analysis may be incomplete
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000017 |
| Document: kros-20260304.htm | 0001664710-26-000017 |
| Document: 0001664710-26-000017-index-headers.html | 0001664710-26-000017 |
| Document: 0001664710-26-000017-index.html | 0001664710-26-000017 |
| Document: 0001664710-26-000017.txt | 0001664710-26-000017 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers